News
Kymera signs $750m cancer deal with Gilead as Sanofi opts in
Kymera is celebrating the signing of two partnerships, with Gilead taking an option on one molecular glue programme, as Sanofi buys into another.
Oncology
ASCO 2025: Breast cancer breakthroughs drive HCPs’ online co...
Every year at ASCO, we see new data. New combinations. New standards of care.
News
Nuvalent chases after Nuvation in ROS1 lung cancer
New trial data sets up a filing for Nuvalent's new-generation ROS1 inhibitor in NSCLC, although it has an uphill battle to catch rival Nuvation.
News
AZ, Daiichi get Datroway nod in lung cancer on second try
AZ and Daiichi Sankyo have claimed FDA approval for Datroway in lung cancer after switching indications for the TROP2-directed drug.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
